Targeting the 5-HT3 receptor in the treatment of irritable bowel syndrome

Irritable bowel syndrome, which affects 5–10% of the population includes around 25% with predominantly diarrhoea (IBS-D). Several lines of evidence suggest an increase in mucosal 5-HT availability in IBS-D including a decrease in the serotonin transporter (SERT) which is also seen following acute di...

Full description

Saved in:
Bibliographic Details
Published in:Current opinion in pharmacology 2011-02, Vol.11 (1), p.68-74
Main Author: Spiller, Robin C
Format: Article
Language:English
Subjects:
Internal Medicine
Medical Education
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Irritable bowel syndrome, which affects 5–10% of the population includes around 25% with predominantly diarrhoea (IBS-D). Several lines of evidence suggest an increase in mucosal 5-HT availability in IBS-D including a decrease in the serotonin transporter (SERT) which is also seen following acute diverticulitis. 5-HT3 receptor antagonists have proved effective in suppressing urgency, prolonging small and large bowel transit and relieving symptoms in IBS-D. Alosetron continues to be used under restricted availability without any serious morbidity despite ischemic colitis which occurs at a rate of
ISSN:1471-4892
DOI:10.1016/j.coph.2011.02.005